W

EU Variation Classification Tool – Type IA, IB or II?

WRPA EU Variation & Readiness Navigator · based on the revised EU Variations framework (guidelines applicable since 15 January 2026)
Weidlich Regulatory & Program Advisory
Free tool — no login, nothing stored on a server

Classify an EU variation, check eCTD v4.0 readiness, and see what the 2023–2028 Pharma Reform means for your product — in under five minutes.

Built against the actual text of the January 2026 EU Variations Guideline (Commission Notice C/2025/5045), the consolidated Variations Regulation (EC) No 1234/2008, and the current EU Pharma Reform legislative file — not a generic summary.

This is draft decision-support, not a regulatory submission or legal opinion. It does not have complete Annex II sub-code coverage and cannot replace a full classification review. Verify every result against the current EMA/national guideline before acting on it — and see the reasoning trail under each result so you can check the logic yourself, not just the answer.

Describe the change(s)

Plain language is fine — describe it the way you'd say it out loud, not as a legal category. Add one row per distinct change if you're planning to submit several together; each gets its own classification, and you'll get one recommended overall submission approach at the end.
Used only to flag which ruleset applies — nothing is stored.
Reasoning grounded in Commission Notice C/2025/5045 (applicable from 15 Jan 2026) and Regulation (EC) No 1234/2008 as consolidated to 01/01/2025. Sourced and cross-checked 2026-08-22 — see WRPA's own regulatory-affairs knowledge base for full citations. Keyword matching is intentionally broad to handle plain-language descriptions — always sanity-check an unexpected result rather than trusting it blindly. The "Concerned CTD part(s)" and "Timeline by phase" blocks under each result use the same keyword-matching approach and the ICH M4 module structure — treat them as a starting checklist, not a formal dossier-impact assessment, and note where a phase's duration is explicitly stated as unconfirmed in the source text rather than guessed.

eCTD v4.0 readiness check

v4.0 is built on HL7 RPS — a single unified XML message with context-group/keyword/priority metadata, replacing v3.2.2's per-sequence backbone messages. For good content, a v4.0 dossier looks similar to v3.2.2; the real learning curve is the new metadata concepts and validated tooling, not the underlying science. Note: "EMA" below means the centralised procedure specifically — if you file via MRP/DCP/national routes, that's a separate, later-moving track (see below), not covered by EMA's own centralised-procedure timeline.
Adoption dates verified against EMA's own published timeline and cross-checked against detailed third-party technical reports (IntuitionLabs; Perceptive; Freyr Solutions) where ICH's/EMA's own sites could not be fetched directly. The EU NCA (MRP/DCP/national) track specifically is reported as separate and less mature than EMA's centralised-procedure track — treat its dates as more provisional than the FDA/EMA/PMDA figures above. Re-check ich.org / your target regulator's site before finalising a project timeline — these dates move.

What the 2023–2028 EU Pharma Reform means for a decision you're actually making

If you're an RA professional, you already know whether your product is orphan-designated or an ATMP — that's not the useful question. The useful question is what a known characteristic means under rules that are still being finalised, and what's genuinely still open versus settled enough to act on. This tab assumes you know your product; it's built to translate, not to diagnose.
This changes which of the open items below actually matter to you — a renewal decision and a licensing valuation care about different unresolved questions.
Based on WRPA's tracked reading of the reform file (procedures 2023/0131(COD) and 2023/0132(COD) on the official EU Law Tracker) as of 2026-08-22. Several figures below (180/150-day CHMP timelines, unlimited MA validity, ERA scope) rest on secondary legal commentary, not yet the adopted text — flagged inline.

Want this checked properly, not just flagged?

This tool is a starting point, not a submission-ready answer. WRPA offers a fixed-scope EU Pharma Reform / eCTD v4.0 / Variation readiness diagnosis — a short, bounded engagement with a concrete gap list and priority plan at the end.

Ask about a readiness diagnosis

How the classification works

Under the revised EU variations framework, changes to a marketing authorisation are classified as Type IA (minor, notify within 12 months or immediately for IAIN), Type IB (minor, notify before implementation) or Type II (major, prior approval). The tool gives a first indication; the binding classification always follows the EU Variations Guidelines and, where unclear, an Article 5 recommendation by the authority. Need a second opinion on a borderline case? Book a 30-minute call.

Interim RA support for variations →